Renalytix AI (GB:RENX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix plc, a leader in AI-driven diagnostics for kidney health, saw its CEO, James McCullough, enhance his stake by purchasing 53,300 shares at £0.075 each, reflecting confidence in the company’s future. This move follows a similar purchase by COO Chris Scott, indicating strong insider belief in Renalytix’s growth potential.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.